BioTeZ provides its own technology for production of affinity columns. During routine operation, such as columns for sample preparation of mycotoxin residue analysis are made.

This technology can also be used as customer service:
We prepare individual columns using your materials, like antibodies, peptides, DNA antisera, immunoconjugates or low-molecular agents, which can be utilized for your own affinity chromatography.

We provide ready-to-use-columns in different dimensions (0,1µl up to 100L). Furthermore, you get a comprehensive manual for proper handling. The own BioTeZ technology guarantees an effective and structure saving couppling of ligands.

Advantages of our columns:

  • Good flow behavior: No elevated pressure is required
  • Low abrasion

References:
Coring Systems Diagnostix GmbH
Dr. Fooke Laboratorien GmbH, Office Neuruppin
Dr. Schade, Charitè Berlin, Institute of Pharmacology

BioTeZ GmbH

Die BioTeZ Berlin-Buch GmbH ist ein Biotechnologie-Unternehmen und wurde 1992 gegründet. BioTeZ ist Partner der Forschung, der Pharmaindustrie und der Labordiagnostik.

  • Biodiagnostika
  • Oligonukleotide
  • Markierte Biomoleküle

Contact

BioTeZ Berlin Buch GmbH
Robert-Rössle-Strasse 10, Haus D 72
13125 Berlin - Germany

Tel: +49 30-9489-2130
Fax: +49 30-9494-509
E-Mail: info@biotez.de
www.biotez.de

Events

MedicaMeet BioTeZ at MEDICA, 12-15 Nov. 2018, Düsseldorf, hall 3, booth G54. 


10th Potsdam Days on Bioanalysis (1./2. November 2018), Potsdam; 
Dr. Janko Brand will give insights in the development projects: recoveryELISA Alirocumab, Evolocumab and PCSK9


SWISS BIOTECH DAY 2018 (3 May 2018, Basel)   Swiss_Biotech_Day
Get Information about diagnostics and biotechnological services we offer: Therapeutic Drug Monitoring, Mycotoxin and Vitamin Analysis, Individual Conjugates, ELISA Development, Oligonucleotides, Human Proteases Research, Streptavidin Coatings, Immobilization Technologies; BioTeZ will summarize outcomes of therapeutic drug monitoring studies with Omalizumab/IgE, Adalimumab/TNF and provide insights into Alirocumab, Evolocumab/PCSK9 recoveryELISA Projects.


Deutsche Biotechnologietage We present at Deutsche Biotechnologietage 18-19 April 2018